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Improved understanding of the pathophysiology of conges- 
tive heart failure has led to a major redirection of therapy for 
this condition during the past 15 years. Vasodilators (I) and 
diuretics (2) have been increasingly applied to improve 
deranged circulatory function through their beneficial effects 
on cardiac preload and afterload. replacing the traditional 
emphasis on positive inotropic therapy to augment impaired 
myocardial contractility. This therapeutic evolution is re- 
flected in a current standard cardiology textbook (3) that, in 
contrast to prior editions, now places diuretics ahead of 
digitalis for treatment of cardiac failure. 
Vasodilator therapy. The most striking change in the 
treatment of heart failure has been the widespread use of 
vasodilators to enhance cardiac performance without the 
disadvantage of increasing myocardial energy requirements 
(4). In addition to improvement of symptoms and function by 
vasodilator drugs (I), recent landmark studies have demon- 
strated that these agents can also reduce the drastic mortal- 
ity rate of patients with heart failure. These salutary results 
have been achieved with hydralazine plus isosorbide dini- 
trate (5) and with the angiotensin-converting enzyme inhib- 
itors enalapril (6) and captopril (7). Because of their unique 
physiologic actions. beneficial cardiac and extracardiac ef- 
fects and favorable clinical results on symptoms, function 
and survival. the angiotensin-converting enzyme inhibitors 
are currently the subject of active investigation to further 
explore their therapeutic potential and indications in the 
treatment and possible prevention of left ventricular dys- 
function and death. 
Angiotensin-converting enzyme inhibitors in cardiac fail- 
ure. Current findings indicate that there are a number of 
mechanisms by which the angiotensin-converting enzyme 
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inhibitors may benefit patients with cardiac failure. The 
primary action of these drugs, attenuation of the activity of 
the renin-angiotensin-aldosterone axis (S), diminishes the 
availability of angiotensin 11 and aldosterone, potent hor- 
monal mediators of vasoconstriction and renal sodium reten- 
tion. The facilitatory role of angiotensin 11 on norepinephrine 
and vasopressin release is thus removed, and there is labo- 
ratory evidence that angiotensin-converting enzyme inhibi- 
tion also stimulates vasodilator prostaglandin synthesis (9). 
These neurohumoral actions improve cardiac output and 
filling pressures (IO,1 I). decreasing symptoms (lO,l2) and 
augmenting functional capacity (12). Additional clinical ef- 
fects may contribute to the prolongation of survival by these 
drugs. Angiotensin-converting enzyme inhibition is associ- 
ated with decreased frequency of ventricular arrhythmias 
(II) in cardiac failure, which may be related to reduced 
norepinephrine levels (IO) and to maintenance of serum 
potassium (I?). In experimental and clinical studies, capto- 
pril has protected against progressive postinfarction left 
ventricular functional (13,14) and morphologic (13-15) dete- 
rioration, with increased survival in animals (IS) and humans 
(7). 
Prophylactic use. These provocative results have stimu- 
lated interest in the potential prophylactic use of angioten- 
sin-converting enzyme inhibitors for early asymptomatic left 
ventricular dysfunction. which is currently under investiga- 
tion in the multicenter Survival and Ventricular Enlargement 
Study (14). Free radical scavenging has been proposed as a 
possible mechanism by which angiotensin-converting en- 
zyme inhibitors may exert a cardioprotective effect. In in 
vitro studies it is independent of angiotensin-converting 
enzyme inhibitor activity and may be limited to agents with 
a sulfhydryl group such as captopril (16). Despite their 
impressive spectrum of salutary actions, the safe and effec- 
tive use of angiotensin-converting enzyme inhibitors re- 
quires an awareness of their adverse effects. including hy- 
potension. hyperkalemia and renal dysfunction. 
Combined captopril-digoxin therapy. Although the clini- 
cal actions of angiotensin-converting enzyme inhibitors have 
been extensively investigated, certain practical aspects of 
their use have not been clarified. Thus, these agents, as well 
as other vasodilators, continue to be generally applied in 
conjunction with digitalis. but the utility of this combination 
has not been rigorously evaluated. In their extensive study in 
this issue of the Jownd, Gheorghiade and colleagues (17) 
assess the separate and combined effects of captopril and 
digoxin in patients with moderate or severe cardiac failure 
(17). They found that the two agents had different and 
complementary effects that resulted in a greater improve- 
ment in hemodynamic function at rest and during exercise 
with their combined administration than with either one 
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given separately, thus providing a rationale for the use of 
both drugs in patients with heart failure. The value of this 
study to the clinician is enhanced by its inclusion of patients 
with generally marked cardiac failure who were evaluated by 
hemodynamic and neurohumoral data at rest and during 
exercise. 
Certain limitations are inevitable in a study of this scope. 
As the authors acknowledge, the investigative protocol was 
not randomized or blinded and the short-term nature of the 
evaluation limits its application to long-term therapy. In 
addition, the two study groups differed in several important 
hemodynamic variables that may have accounted for some 
of the differences in results with captopril and digoxin. 
Nevertheless, the findings in this investigation extend our 
knowledge in an important area of clinical management and 
provide a stimulus for further research to clarify remaining 
questions. 
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